Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.
Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.
复制标题
DOI：
10.1371/journal.pone.0022707
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Zhang F
中科院分区：
文献类型：
--
作者：
Dou Z;Xu J;Jiao JH;Ma Y;Durako S;Yu L;Zhao Y;Zhang F
自2002年启动以来，中国免费抗逆转录病毒治疗（ART）项目已从应急响应发展为规范的治疗和护理体系。截至2009年12月31日，全国31个省、自治区、直辖市共81,880例患者接受了免费抗逆转录病毒治疗，但该队列的死亡率和抗逆转录病毒治疗的免疫反应的性别差异尚未得到描述。了解参加中国国家免费ART项目的女性和男性是否对治疗反应同样好。对2006年6月至2008年12月的国家免费ART数据库进行了回顾性分析。本研究纳入了18岁或18岁以上、基线时未接受过ART治疗、2006年6月1日至12月31日期间参加该项目并接受3 TC方案治疗的HIV感染受试者，然后随访2年。在3457例符合入选标准的入组受试者中，59.2%为男性，40.8%为女性。大多数受试者年龄为19-44岁（77%），已婚（72%）。在整个24个月的随访期间，男性的死亡率为19.0%，女性为11.4%（p = 0.0014）。 调整基线特征后，接受治疗3-24个月的男性比女性更可能死亡（HR = 1.46，95% CI：1.04-2.06，p =0.0307）。 与男性相比，女性在开始ART后随着时间的推移CD 4+计数更高（p<0.0001）。我们的研究表明，女性在ART治疗中的死亡率总体上低于男性，CD 4+计数高于男性，这可能归因于依从性，生物因素，社会，文化和经济原因。需要进一步的研究来探讨这些因素可能导致死亡率和对ART的免疫反应的性别差异。
Since it was initiated in 2002, the China Free Antiretroviral Treatment (ART) Program has been progressing from an emergency response to a standardized treatment and care system. As of December 31, 2009, a total of 81,880 patients in 31 provinces, autonomous regions, and special municipalities received free ART. Gender differences, however, in mortality and immunological response to ART in this cohort have never been described. To understand whether women and men who enrolled in the China National Free ART Program responded equally well to the treatment. A retrospective analysis of the national free ART databases from June 2006–December 2008 was performed. HIV-infected subjects who were 18 years or older, ART naïve at baseline, and on a 3TC regimen enrolled in the program from June 1 to December 31, 2006, were included in this study, then followed up to 2 years. Among 3457 enrolled subjects who met the inclusion criteria, 59.2% were male and 40.8% female. The majority of the subjects were 19–44 years old (77%) and married (72%). Over the full 24 months of follow-up, the mortality rate was 19.0% in males and 11.4% in females (p = 0.0014). Males on therapy for 3–24 months were more likely to die than females (HR = 1.46, 95% CI: 1.04–2.06, p = 0.0307) after adjusting for baseline characteristics. Compared to men, women had higher CD4+ counts over time after initiating ART (p<0.0001). Our study showed that women had an overall lower mortality and higher CD4+ counts than men in response to ART treatment, which may be attributed to adherence, biological factors, social, cultural and economic reasons. Further study is needed to explore these factors that might contribute to the gender differences in mortality and immunological response to ART.
登录
查看更多内容
影响因子：
158.5
作者：
Sterling, TR;Vlahov, D;Quinn, TC
通讯作者：
Quinn, TC
性别和收入对南非抗逆转录病毒疗法计划中生存和保留的影响。
DOI：
10.1111/j.1365-3156.2009.02290.x
发表时间：
2009-07
期刊：
Tropical medicine & international health : TM & IH
影响因子：
--
作者：
Cornell M;Myer L;Kaplan R;Bekker LG;Wood R
通讯作者：
Wood R
影响因子：
3.8
作者：
van Sighem, AI;van de Wiel, MA;de Wolf, F
通讯作者：
de Wolf, F
影响因子：
3.8
作者：
Kaleebu, P.;Pillay, D.;Serwadda, D.
通讯作者：
Serwadda, D.
影响因子：
3.8
作者：
Moore, J;Schuman, P;Smith, D
通讯作者：
Smith, D